A case report of late‐onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review

A case report of late‐onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review

Abstract Background and aims Interferon beta (IFNβ) is a well‐established first‐line therapy for relapsing–remitting multiple sclerosis (RRMS) patients and remains the most widely prescribed agent. Atypical hemolytic uremic syndrome (aHUS) represents a rare but severe adverse effect (AE) that could...

Full description

Bibliographic Details
Main Authors: Mosè Parisi, Alessia Manni, Francesca Caputo, Maria Trojano, Damiano Paolicelli
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Brain and Behavior
Subjects:
adverse effects
immunomodulatory therapy
multiple sclerosis
Online Access:https://doi.org/10.1002/brb3.1930

Internet

https://doi.org/10.1002/brb3.1930

Similar Items